Search research articles
Contact Us
Filters
Showing results (101-110 of 148) with videos related to
Page
of 15
Sort By:
Journal of Pain and Symptom Management
|
April 1, 1997
Improving cancer pain management in communities: main results from a randomized controlled trial
T E Elliott, D M Murray, M M Oken, et al.
Investigational New Drugs
|
May 1, 1990
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer
D S Ettinger, D M Finkelstein, M D Abeloff, et al.
Leukemia
|
October 1, 1992
Phase II clinical trial of carboplatin in relapsed and refractory leukemia
W R Vogler, D P Harrington, E F Winton, et al.
Leukemia
|
August 15, 2000
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483)
C Robles, K M Kim, M M Oken, et al.
Journal of Pain and Symptom Management
|
October 1, 1995
Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project
T E Elliott, D M Murray, B A Elliott, et al.
British Journal of Haematology
|
June 10, 2000
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients
R Fonseca, M C Trendle, T Leong, et al.
Leukemia & Lymphoma
|
June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
P H Wiernik, T Leong, M M Oken, et al.
Investigational New Drugs
|
January 1, 1995
A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma
R S Witte, T Leong, M S Ernstoff, et al.
Blood
|
October 1, 1996
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial
P Liu, T Leong, L Quam, et al.
Leukemia & Lymphoma
|
February 1, 1996
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma
M M Oken, R A Kyle, P R Greipp, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 148) with videos related to
Sort By:
Page
of 15
Journal of Pain and Symptom Management
|
April 1, 1997
Improving cancer pain management in communities: main results from a randomized controlled trial
T E Elliott, D M Murray, M M Oken, et al.
Investigational New Drugs
|
May 1, 1990
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer
D S Ettinger, D M Finkelstein, M D Abeloff, et al.
Leukemia
|
October 1, 1992
Phase II clinical trial of carboplatin in relapsed and refractory leukemia
W R Vogler, D P Harrington, E F Winton, et al.
Leukemia
|
August 15, 2000
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483)
C Robles, K M Kim, M M Oken, et al.
Journal of Pain and Symptom Management
|
October 1, 1995
Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project
T E Elliott, D M Murray, B A Elliott, et al.
British Journal of Haematology
|
June 10, 2000
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients
R Fonseca, M C Trendle, T Leong, et al.
Leukemia & Lymphoma
|
June 28, 2001
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
P H Wiernik, T Leong, M M Oken, et al.
Investigational New Drugs
|
January 1, 1995
A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma
R S Witte, T Leong, M S Ernstoff, et al.
Blood
|
October 1, 1996
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial
P Liu, T Leong, L Quam, et al.
Leukemia & Lymphoma
|
February 1, 1996
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma
M M Oken, R A Kyle, P R Greipp, et al.
Page
of 15